"Revivicor, Inc. - Product Pipeline Analysis, 2013 Update" is now available at Fast Market Research

Revivicor, Inc. (Revivicor) is a regenerative medicine company. The company uses animal biotechnology platforms to provide alternative tissue source for treatment of human degenerative disease. Its technologies include xenotransplantation, islet transplantation, and infectious disease technology. Revivicor provides genetically engineered pigs to provide human compatible cells to treat diabetes, and organs and tissues for use in transplant surgery. The company's infectious disease technology platform produces therapeutic fully human polyclonal antibodies for the treatment of various infectious diseases. It also uses gene targeting and pig cloning technology to inactivate the pig immunoglobulin (Ig) or antibody coding genes. The company partners with medical device industry for orthopedic and skin-derived products, which are derived from its GalSafe pigs. Revivicor is headquartered in Blacksburg, Virginia, the US.

Full Report Details at
- http://www.fastmr.com/prod/652438_revivicor_inc_product_pipeline_analysis_2013.aspx?afid=301

This report is a source for data, analysis and actionable intelligence on the Revivicor, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

* Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
* Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
* Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
* Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
* Data on relevant clinical trials and product patent details, wherever applicable.
* Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Get this Report

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- GE Healthcare - Product Pipeline Analysis , 2013 Update
- Philips Healthcare - Product Pipeline Analysis, 2013 Update
- Boston Scientific Corporation (BSX) - Product Pipeline Analysis, 2013 Update
- St. Jude Medical, Inc. (STJ) - Product Pipeline Analysis, 2013 Update
- Siemens Healthcare - Product Pipeline Analysis, 2013 Update